Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Objective: Spinocerebellar ataxia type 3 (SCA3), also known as Machado–Joseph disease, is the most common dominantly inherited ataxia. Despite advances in understanding this CAG repeat/polyglutamine expansion disease, there are still no therapies to alter its progressive fatal course. Here, we investigate whether an antisense oligonucleotide (ASO) targeting the SCA3 disease gene, ATXN3 , can prevent molecular, neuropathological, electrophysiological, and behavioral features of the disease in a mouse model of SCA3. Methods: The top ATXN3‐ targeting ASO from an in vivo screen was injected intracerebroventricularly into early symptomatic transgenic SCA3 mice that express the full human disease gene and recapitulate key disease features. Following a single ASO treatment at 8 weeks of age, mice were evaluated longitudinally for ATXN3 suppression and rescue of disease‐associated pathological changes. Mice receiving an additional repeat injection at 21 weeks were evaluated longitudinally up to 29 weeks for motor performance. Results: The ATXN3 ‐targeting ASO achieved sustained reduction of polyglutamine‐expanded ATXN3 up to 8 weeks after treatment and prevented oligomeric and nuclear accumulation of ATXN3 up to at least 14 weeks after treatment. Longitudinal ASO therapy rescued motor impairment in SCA3 mice, and this rescue was associated with a recovery of defects in Purkinje neuron firing frequency and afterhyperpolarization. Interpretation: This preclinical study established efficacy of ATXN3 ‐targeted ASOs as a disease‐modifying therapeutic strategy for SCA3. These results support further efforts to develop ASOs for human clinical trials in this polyglutamine disease as well as in other dominantly inherited disorders caused by toxic gain of function. Ann Neurol 2018;83:64–77
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., Chiriboga, C. A., Saito, K., Servais, L., Tizzano, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702752 · Cited by 2,337 · cited 1×
“Food and Drug Administration (FDA) and European Medicines Agency following successful human clinical trials.(12,13) Our group and others previously tested nucleotidebased gene silencing strategies as potential diseasemodifying therapy in SCA3, including viral-mediated RNA interference and exon-skipping approaches.”
BackgroundThe roles of intracellular protein-degradation pathways in neurodegeneration
Rubinsztein, D. C. (2006) · Nature · doi:10.1038/nature05291 · Cited by 1,625
Kordasiewicz, H. B., Stanek, L. M., Wancewicz, E. V., Mazur, C., McAlonis, M. M., Pytel, K. A., Artates, J. W., Weiss, A., Cheng, S. H., Shihabuddin, L. S., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.05.009 · Cited by 770 · cited 2×
“These results further support the growing evidence from preclinical animal and human clinical ASO trials demonstrating sustained, widespread, and well-tolerated ASO delivery to the CNS following longitudinal ICV or intrathecal delivery.(20,22) In support of the tolerability of ASOs for SCA3, recent elegant work from T…”
BackgroundResultSelf-citationPolyglutamine tracts regulate beclin 1-dependent autophagy
Ashkenazi, A., Bento, C. F., Ricketts, T., Vicinanza, M., Siddiqi, F., Pavel, M., Squitieri, F., Hardenberg, M. C., Imarisio, S., Menzies, F. M., et al. (2017) · Nature · doi:10.1038/nature22078 · Cited by 357
Antisense oligonucleotide therapy for spinocerebellar ataxia type 2
Scoles, D. R., Meera, P., Schneider, M. D., Paul, S., Dansithong, W., Figueroa, K. P., Hung, G., Rigo, F., Bennett, C. F., Otis, T. S., et al. (2017) · Nature · doi:10.1038/nature22044 · Cited by 319
Antisense oligonucleotides: translation from mouse models to human neurodegenerative diseases
Schoch, K. M., & Miller, T. M. (2017) · Neuron · doi:10.1016/j.neuron.2017.04.010 · Cited by 274 · cited 1×
“Gliosis occurs in SCA3(3,30) and can also be a potential adverse effect of ASO treatment.(31) To determine the tolerability of ASOs at increasing doses, treated mice were assessed for astrogliosis and microgliosis 4 weeks after treatment.”
BackgroundLieberman, A. P., Yu, Z., Murray, S., Peralta, R., Low, A., Guo, S., Yu, X. X., Cortes, C. J., Bennett, C. F., Monia, B. P., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.008 · Cited by 169 · cited 1×
“In addition to the current preclinical longitudinal study, ASO preclinical development has been completed for several other polyglutamine diseases, with sustained ASOmediated phenotypic rescue similarly reported.(20,22,49,50) Notably, the very ASO assessed here, ASO-5, possesses the same ASO chemistry as a therapeutic…”
BackgroundNascimento-Ferreira, I., Nóbrega, C., Vasconcelos-Ferreira, A., Onofre, I., Albuquerque, D., Aveleira, C., Hirai, H., Déglon, N., & Pereira de Almeida, L. (2013) · Brain · doi:10.1093/brain/awt144 · Cited by 96 · cited 1×
“A recent report suggests that, in addition to autophagy’s role in regulating clearance of misfolded proteins like polyglutamine-expanded ATXN3, autophagy may itself be regulated by ATXN3 in normal and disease states.(39,40) Specifically, WT ATXN3 has been reported to stabilize the essential autophagy adapter protein b…”
BackgroundDell’Orco, J. M., Pulst, S. M., & Shakkottai, V. G. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx281 · Cited by 65
Self-citation
Cited by
Klockgether, T., Mariotti, C., & Paulson, H. L. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0074-3 · Cited by 696
Self-citationJafar-nejad, P., Powers, B., Soriano, A., Zhao, H., Norris, D. A., Matson, J., DeBrosse-Serra, B., Watson, J., Narayanan, P., Chun, S. J., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa1235 · Cited by 128
“Over the years, centrally administered ASOs have demonstrated widespread CNS tissue distribution, activity, and substantial phenotypic prevention and/or even reversal in mouse models of Huntington’s (8), SMA (9), Frontotemporal dementia (10), Parkinson’s (11), TDP-43- and C9orf72-linked ALS (12), Alexander disease (13…”
BackgroundSelf-citationFriedrich, J., Kordasiewicz, H. B., O’Callaghan, B., Handler, H. P., Wagener, C., Duvick, L., Swayze, E. E., Rainwater, O., Hofstra, B., Benneyworth, M., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.123193 · Cited by 121
Self-citationAntisense drugs make sense for neurological diseases
Bennett, C. F., Kordasiewicz, H. B., & Cleveland, D. W. (2021) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023738 · Cited by 108
“ASOmediated lowering of ATXN3 results in reversal of nuclear ATXN3 accumulation, dosedependent clearance of soluble and high molecular weight species, mitigation of motor deficits, repair of cerebellar network dysfunction, and gene expression changes (63; 150; 151).”
BackgroundSelf-citation
Metadata
- Authors
- McLoughlin, H. S., Moore, L. R., Chopra, R., Komlo, R., McKenzie, M., Blumenstein, K. G., Zhao, H., Kordasiewicz, H. B., Shakkottai, V. G., & Paulson, H. L.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2018-07
- Volume
- 84
- Issue
- 1
- Pages
- 64-77
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2808202810
- Cited by
- 144
- References
- 9
- FWCI
- 7.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice. https://app.cochat.ai/papers/10.1002/ana.25264
- The paper
- McLoughlin, H. S., Moore, L. R., Chopra, R., Komlo, R., McKenzie, M., Blumenstein, K. G., Zhao, H., Kordasiewicz, H. B., Shakkottai, V. G., & Paulson, H. L. (2018). Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice. Annals of Neurology. https://doi.org/10.1002/ana.25264
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.